ISIN IE000O5M6XO1

ARK Genomic Revolution UCITS ETF

ARK Genomic Revolution UCITS ETF is an equity ETF, ISIN IE000O5M6XO1.

  • Equity
  • Equity Health Care

No material from any part of this website may be distributed, transferred, reproduced, retransmitted, modified, published, publicly displayed or otherwise disseminated in any form to any person or entity, without obtaining the explicit written consent of IQ EQ unless for the purpose of regulatory disclosure.

How the fund has returned, and where it ranks among peers. Returns to Sep 2026 end, GBP net total return.
+96.6% Q1
1 year return
–
3 year return
–
5 year return
Daily NAV, percent change from the start of the range. Source: FE fundinfo.
  • 1 month +16.6%
  • 3 months +26.8%
  • Ongoing charge (OCF)

What the fund holds

Where the money is: sectors, countries and largest holdings. As supplied by FE fundinfo, last updated 17 Oct 2026. Swipe or use the arrows for more panels.

By sector

Spot concentrations at a glance. Share of the fund's portfolio, as supplied by FE fundinfo, last updated 17 Oct 2026.
Others100.0%

By country

Spot concentrations at a glance. Share of the fund's portfolio, as supplied by FE fundinfo, last updated 17 Oct 2026.
International100.0%

By asset class

Spot concentrations at a glance. Share of the fund's portfolio, as supplied by FE fundinfo, last updated 17 Oct 2026.
International Equities100.0%

Largest holdings

The biggest positions, and how concentrated the fund is. As supplied by FE fundinfo, last updated 17 Oct 2026.
  1. 1. TWIST BIOSCIENCE CORPORATION9.4%
  2. 2. TEMPUS AI INC8.1%
  3. 3. 10X GENOMICS INC6.7%
  4. 4. CRISPR THERAPEUTICS AG5.8%
  5. 5. PERSONALIS INC5.0%
See all holdingsA free account shows the full list.

Macro events and this fund

Recent events linked to this fund by its country and sector exposure, and how it moved after. A measured move, not a cause.

Performance, risk and facts

Judge return, risk and cost before a client conversation. Relative return uses the chart's time range. Facts as reported by the manager.

Against its benchmark

How the fund compares with its benchmark over the same period.

Risk

How bumpy the ride has been, plus the regulatory risk rating.

Volatility and maximum drawdown are not available for this fund.

Fund facts

Legal and cost facts for a client note. As reported by the manager.
ISIN
IE000O5M6XO1
Benchmark
N/A
Ongoing charge
Share class launch date
12 Apr 2024
Domicile
IE
Fund type
open-ended fund
SRRI
6 of 7

What a sum would have become

What an amount would have grown to over the period.
n/a

Past performance is not a reliable guide to future returns. Capital is at risk. Source: FE fundinfo. Returns are GBP net total return to month end unless stated. Headline returns to Sep 2026. Fund size is shown in GBP.

Top country exposure